A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult Community- Acquired Complicated Intra-abdominal Infections

Trial Profile

A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult Community- Acquired Complicated Intra-abdominal Infections

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Eravacycline (Primary) ; Ertapenem
  • Indications Gram-negative infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Sponsors Tetraphase Pharmaceuticals
  • Most Recent Events

    • 16 Dec 2013 Results published in the Antimicrobial Agents and Chemotherapy.
    • 04 Sep 2013 Results will be presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013) according to a Trius Therapeutics media release.
    • 29 Apr 2013 Results presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting, according to a Trius Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top